Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Emma Steidel"'
Autor:
Nora Muehlegger, Ursula Creutzig, Emma Steidel, Jan Stary, Dirk Reinhardt, Lucie Sramkova, Christiane Walter, Naghmeh Niktoreh, Nils von Neuhoff, Heidrun Boztug, Thomas Lehrnbecher, Jean-Pierre Bourquin, Michael Dworzak, Iveta Janotova, Mareike Rasche, Martin Zimmermann, Edward A. Kolb
Publikováno v:
Cancers, Vol 13, Iss 789, p 789 (2021)
Cancers
Volume 13
Issue 4
Cancers
Volume 13
Issue 4
Successful management of relapse is critical to improve outcomes of children with acute myeloid leukemia (AML). We evaluated response, survival and prognostic factors after a second relapse of AML. Among 1222 pediatric patients of the population-base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90173760db6dc24a9f98249fddf7de1e
https://pubmed.ncbi.nlm.nih.gov/33672815
https://pubmed.ncbi.nlm.nih.gov/33672815
Autor:
Jean-Pierre Bourquin, Dirk Reinhardt, Nora Muehlegger, Iveta Janotova, Ursula Creutzig, Alan S. Gamis, Jan Stary, Edward A. Kolb, Robert B. Gerbing, Martin Zimmermann, Emma Steidel, Mareike Rasche, Richard Aplenc, Naghmeh Niktoreh, Thomas Lehrnbecher, Todd A. Alonzo, Lucie Sramkova, Michael Dworzak, Nils von Neuhoff, Christiane Walter, Heidrun Boztug
Publikováno v:
Blood. 136:6-7
BACKGROUND: Children with high risk acute myeloid leukemia (AML) still experience consistently high rates of relapse. Survival after first relapse increased from 21% between 1987 and 1997 up to 39% in recent studies. However, since 2009, there have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::559424b70a219897dabf3bb1b1e253ae
https://doi.org/10.1182/blood-2020-141774
https://doi.org/10.1182/blood-2020-141774
Autor:
Emma Steidel, Mareike Rasche, Michael Dworzak, Nils von Neuhoff, Lucie Sramkova, Dirk Reinhardt, Ursula Creutzig, Denise Kondryn
Publikováno v:
Blood. 134:293-293
BACKGROUND: A risk-adapted approach incorporating genetic data, complemented by response evaluation may help to identify patients with high-risk disease (HR) who could benefit from hematopoietic stem cell transplantation (HSCT) at initial disease. Se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecf4fbc6fa1e704bcb073fed81046ac9
https://doi.org/10.1182/blood-2019-130969
https://doi.org/10.1182/blood-2019-130969